Search Results

Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy

The project builds on evidence that mutations leading to persistent EZH2 activation drive germinal center B-cell lymphomagenesis by disrupting T-cell surveillance, and will test the hypothesis that EZH2 inhibition synergizes with immune checkpoint blockade and/or co-stimulation to eradicate these diseases. These results will provide the rationale for clinical development of precision-medicine immune-epigenetic combination therapies for lymphomas where these mechanisms are specifically altered.

Loncastuximab

Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. 

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast

Black and Hispanic individuals diagnosed with Hodgkin lymphoma (HL) face worse survival rates across all ages. Using an innovative data source, this study will examine differences by insurance status in the receipt and quality of HL treatment in Aim 1 and care engagement and support after treatment (survivorship care) in Aim 2. Using diverse patient voices, this study will characterize and understand how patients make decisions about treatment and survivorship care by insurance type in Aim 3.

Pralatrexate

Pralatrexate is FDA approved to treat people who have relapsed or refractory peripheral T-cell lymphoma. It is being studied to treat people who have other forms of lymphoma including diffuse large B-cell lymphoma.

Non-Hodgkin Lymphoma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Signs and Symptoms

Lymphoma patient and family give back

Living with Cutaneous T-cell Lymphoma

Edward Jones & The Leukemia & Lymphoma Society

How is Mantle Cell Lymphoma Treated?

Attention Hodgkin Lymphoma Patients and Caregivers!

Research Accelerator for Follicular Lymphoma I (RAFL-I)

Preventing follicular lymphoma progression and transformation through precision therapy

Follicular lymphomas (FL) depend on stromal cells for survival and proliferation and evade T-cell immune surveillance. Although indolent, most FLs eventually undergo either progression or transformation to an aggressive lymphoma. Effective treatments to prevent this remain a critical unmet need. This proposal will develop novel, mechanism-based therapeutic regimens for FL that overcome defective immune surveillance, prevent FLs from receiving stromal support and prevent disease progression.

Immunotherapies on a Roll at #ASH20

More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.

Looking Ahead: LLS Panel Highlights Trends and Advances

The Leukemia & Lymphoma Society recently brought together a world-renowned panel of thought leaders to discuss the latest advances and insights into blood cancer research and treatment, drug costs and patient access, and patient advocacy and policy.

 “There’s never a good time to get cancer but this is a phenomenal time to be fighting it,” said Louis J. DeGennaro, president and CEO of The Leukemia & Lymphoma Society (LLS).

Meet The Researcher: Dr. Christopher R. Flowers

Zanubrutinib

Zanubrutinib is indicated for the treatment of adult patients with:

World-Renowned Chef & Cancer Survivor Cooks for a Cure

Shortly before Steve McHugh and his wife moved to San Antonio in 2010, the rising star chef was diagnosed with non-Hodgkin lymphoma and spent a year undergoing eight rounds of chemotherapy.

“Chemotherapy was a real roller coaster – I experienced insomnia, constipation and dizzy spells. There were times I would not sleep for three to four days,” he said.

2018 Nobel Prize in Physiology or Medicine: Unleashing the Immune System

The Nobel Prize in Physiology or Medicine has been awarded today to two scientists whose groundbreaking work led to the development of a class of immunotherapies called checkpoint inhibitors that work by releasing the brakes on the immune system.

Glofitamab-gxbm

Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. 

Tazemetostat

Tazemetostat is a methyltransferase inhibitor indicated for the treatment of:

Finding New Approaches to Immunotherapy

Translating molecular profiles into treatment approaches to target disparities in lymphoma

Although many patients with diffuse large B-cell lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significantly worse for African American (AA) patients and those with Epstein- Barr virus (EBV), which is common in patients from Latin America. The reasons behind these poor outcomes are not well understood, in part because most studies of molecular features in lymphomas have not included enough patients from these racial and ethnic groups.

The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Certain Patients with Mantle Cell Lymphoma